Testing a new eye drop bottle for glaucoma
Part of Eyes & vision clinical trials.
This study checks whether a device called the Nanodropper helps deliver glaucoma medicine as well as standard use. It is for adults with stable primary open-angle glaucoma (or ocular hypertension) who are on a limited number of eye-pressure medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have primary open-angle glaucoma or ocular hypertension
- You take no more than 2 eye-pressure–lowering medicines
- Your condition has been stable with no worsening over the last year
- You have not had eye-pressure surgery or laser treatment recently (except SLT done at least 6 months ago)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an eye drop (G01) for people with primary open-angle glaucoma that is getting worse despite current treatments. It aims to see if G01 can safely slow down or stop the progression of glaucoma.
This study tests a new eye drop medicine (DNN.31.19.026) to lower pressure inside the eye for people with glaucoma or ocular hypertension. The goal is to see if it works safely when combined with other eye pressure medications.
This trial tests a new medicine called HUC3-637 for people with primary open-angle glaucoma or ocular hypertension. It aims to see if it safely lowers eye pressure.
This study tests whether three different eye drop treatments (netarsudil, latanoprost, or both together) can improve blood flow to the white part of the eye and the retina. It may help people with high eye pressure or who are glaucoma suspects better understand how these treatments work.
This study measures inflammation markers on the eye surface in people with primary open-angle glaucoma or ocular hypertension who use certain glaucoma drops. The results may help doctors understand how these drops affect the eye and inflammation.
This trial tests a new eye drop combination (TFC-003) to lower eye pressure in people with primary open-angle glaucoma or ocular hypertension. It compares the new drug to existing treatments to see if it works better or is safer.
Hear when a new Ocular Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.